Target Price | $137.91 |
Price | $126.88 |
Potential |
8.69%
register free of charge
|
Number of Estimates | 21 |
21 Analysts have issued a price target Abbott Laboratories 2026 .
The average Abbott Laboratories target price is $137.91.
This is
8.69%
register free of charge
$158.00
24.53%
register free of charge
$117.00
7.79%
register free of charge
|
|
A rating was issued by 29 analysts: 19 Analysts recommend Abbott Laboratories to buy, 9 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Abbott Laboratories stock has an average upside potential 2026 of
8.69%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 41.95 | 44.36 |
4.59% | 5.75% | |
EBITDA Margin | 24.00% | 26.58% |
0.53% | 10.74% | |
Net Margin | 31.54% | 15.37% |
124.07% | 51.27% |
23 Analysts have issued a sales forecast Abbott Laboratories 2025 . The average Abbott Laboratories sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Abbott Laboratories EBITDA forecast 2025. The average Abbott Laboratories EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Abbott Laboratories Analysts have issued a net profit forecast 2025. The average Abbott Laboratories net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 7.64 | 3.94 |
134.36% | 48.43% | |
P/E | 32.22 | |
EV/Sales | 5.13 |
11 Analysts have issued a Abbott Laboratories forecast for earnings per share. The average Abbott Laboratories EPS is
This results in the following potential growth metrics and future valuations:
Abbott Laboratories...
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Jan 27 2025 |
UBS |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
Stifel |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
Analyst Rating | Date |
---|---|
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 10 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Jan 27 2025 |
Locked
UBS:
Locked
➜
Locked
|
Jan 23 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Jan 23 2025 |
Locked
Stifel:
Locked
➜
Locked
|
Jan 23 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.